We are live on
!
Find out more
AC
Ascend Capital Portfolio holdings
AUM
$1.99B
1-Year Est. Return
10.36%
This Fund
S&P 500
This Quarter
Est. Return
+5.95%
1 Year Est. Return
+10.36%
3 Year Est. Return
+56.79%
5 Year Est. Return
+86.43%
10 Year Est. Return
–
AUM
$2.65B
AUM Growth
+$502M
(+23%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
4.8%
Top 10 Holdings %
Top 10 Hldgs %
26.96%
Holding
215
New
70
Increased
41
Reduced
38
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Host Hotels & Resorts
HST
|
+$61.6M |
| 2 |
Puma Biotechnology
PBYI
|
+$61.1M |
| 3 |
Prudential Financial
PRU
|
+$61M |
| 4 |
Viatris
VTRS
|
+$49.3M |
| 5 |
ANDV
Andeavor
ANDV
|
+$49.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MetLife
MET
|
+$53.9M |
| 2 |
Tapestry
TPR
|
+$32.5M |
| 3 |
Pfizer
PFE
|
+$32.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$30.7M |
| 5 |
Kraft Heinz
KHC
|
+$30.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 14.41% |
| 2 | Healthcare | 14.35% |
| 3 | Technology | 11.67% |
| 4 | Energy | 8.22% |
| 5 | Materials | 7.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
XPO
XPO
$23.4B
| $14.9M | 0.56% |
636,046
+196,762
| +45% | +$4.12M |
|
52
Air Products & Chemicals
APD
$65.5B
| $14.4M | 0.54% |
95,527
-144,957
| -60% | -$21.2M |
|
53
Eastman Chemical
EMN
$7.69B
| $14.4M | 0.54% |
159,354
-102,477
| -39% | -$8.72M |
|
|
SRCL
54
DELISTED
Stericycle Inc
SRCL
| $14.2M | 0.54% |
+198,687
| New | +$14.6M |
|
55
Ametek
AME
$53.9B
| $14.2M | 0.54% |
+215,277
| New | +$13.6M |
|
56
DXC Technology
DXC
$1.91B
| $14.1M | 0.53% |
189,663
-157,888
| -45% | -$11.2M |
|
57
iShare MSCI Eurozone ETF
EZU
$9.38B
| $13.8M | 0.52% |
318,870
-220,938
| -41% | -$9.25M |
|
|
GBT
58
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $13.7M | 0.52% |
441,674
+82,390
| +23% | +$2.32M |
|
59
GoDaddy
GDDY
$13.9B
| $13.7M | 0.52% |
313,929
+103,396
| +49% | +$4.46M |
|
60
NovoCure
NVCR
$1.76B
| $13M | 0.49% |
+654,152
| New | +$12.9M |
|
61
Constellium
CSTM
$3.76B
| $12.5M | 0.47% |
1,219,462
+305,790
| +33% | +$2.9M |
|
62
Compass Minerals
CMP
$1.23B
| $12.3M | 0.47% |
+190,146
| New | +$12.7M |
|
|
EFII
63
DELISTED
Electronics for Imaging
EFII
| $12M | 0.45% |
280,988
-154
| -0.1% | -$6.3K |
|
64
Dentsply Sirona
XRAY
$2.84B
| $11.5M | 0.43% |
192,096
+10,166
| +6% | +$604K |
|
65
Regenxbio
RGNX
$616M
| $11.3M | 0.43% |
344,287
+57,299
| +20% | +$1.29M |
|
66
Comcast
CMCSA
$87.3B
| $11M | 0.41% |
285,299
+130,084
| +84% | +$5.12M |
|
67
OneMain Financial
OMF
$7.27B
| $10.8M | 0.41% |
+381,332
| New | +$10.2M |
|
|
DATA
68
DELISTED
Tableau Software, Inc.
DATA
| $10.7M | 0.4% |
143,150
-61,436
| -30% | -$4.27M |
|
|
CALA
69
DELISTED
Calithera Biosciences, Inc
CALA
| $10.4M | 0.39% |
32,910
+12,230
| +59% | +$3.86M |
|
70
Brighthouse Financial
BHF
$3.61B
| $9.74M | 0.37% |
+160,164
| New | +$9.14M |
|
71
Citigroup
C
$213B
| $9.6M | 0.36% |
131,949
+97,972
| +288% | +$6.69M |
|
72
Visa
V
$701B
| $9.41M | 0.36% |
89,422
-139,138
| -61% | -$14.1M |
|
73
Dover
DOV
$26.7B
| $9.2M | 0.35% |
+124,646
| New | +$8.66M |
|
74
Ecovyst
ECVT
$1.32B
| $9.03M | 0.34% |
+523,744
| New | +$9.03M |
|
75
Bank of America
BAC
$429B
| $8.97M | 0.34% |
+353,782
| New | +$8.59M |
|
Similar funds
MWAC
TP
PC
RW
TBC
BWCA
AC
GCM
Ascend Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Ascend Capital held 215 positions worth $2.65B, up 23% from $2.15B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Ascend Capital deployed $127M of net new capital in Q3 2017, opening 70 new positions and adding to 41 existing holdings. Its largest new stake was Host Hotels & Resorts: 3,386,281 shares worth $62.6M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 14% of assets, down from 15% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was MetLife, an estimated $53.9M trimmed.
- Ascend Capital's largest Q3 2017 buy was Host Hotels & Resorts: 3,386,281 shares worth $62.6M.
- Ascend Capital added most to Puma Biotechnology in Q3 2017, an estimated $61.1M increase.
- Ascend Capital's biggest Q3 2017 reduction was MetLife, cutting an estimated $53.9M.
- Ascend Capital fully exited Tapestry in Q3 2017, selling an estimated $32.5M.
- Ascend Capital's ten largest holdings make up 27% of its $2.65B portfolio in Q3 2017.
- Ascend Capital opened 70 new positions and closed 54 in Q3 2017.
- Ascend Capital's portfolio value rose 23% quarter-over-quarter to $2.65B.
Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.